Skip to main content
JAMA
Opening the FDA black box.
Statins for Primary Prevention: The Debate Is Intense, but the Data Are Weak.
Power Morcellators, Postmarketing Surveillance, and the US Food and Drug Administration.
Characteristics of Clinical Studies Used for US Food and Drug Administration Approval of High-Risk Medical Device Supplements.
Death by Gun Violence-A Public Health Crisis.
Management of Anticoagulation in Patients With Atrial Fibrillation.
Association of single- vs dual-chamber ICDs with mortality, readmissions, and complications among patients receiving an ICD for primary prevention.
Long-term outcomes of left anterior fascicular block in the absence of overt cardiovascular disease.
Implications of hypertrophic cardiomyopathy transmitted by sperm donation.
Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease.
